Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Nature Communications|February 28, 2023
Engineering potent live attenuated coronavirus vaccines by targeted inactivation of the immune evasive viral deubiquitinaseSebenzile K Myeni, Peter J Bredenbeek, Robert C M Knaap, et al.
Gut|January 6, 2022
Humoral response to SARS-CoV-2 infection among liver transplant recipientsChiara Becchetti, Annelotte G C Broekhoven, Géraldine Dahlqvist, et al.
Plos Pathogens|March 25, 2024
Deubiquitinating activity of SARS-CoV-2 papain-like protease does not influence virus replication or innate immune responses in vivoMariska van Huizen, Jonna R Bloeme-Ter Horst, Heidi L M de Gruyter, et al.
Scientific Reports|March 8, 2024
Impact of SARS-CoV-2 spike stability and RBD exposure on antigenicity and immunogenicityLucy Rutten, Maarten Swart, Annemart Koornneef, et al.
NPJ Vaccines|October 21, 2020
Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responsesRinke Bos, Lucy Rutten, Joan E M van der Lubbe, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|March 29, 2024
Intradermal delivery of the third dose of the mRNA-1273 SARS-CoV-2 vaccine: safety and immunogenicity of a fractional booster doseGeert V T Roozen, Manon L M Prins, Corine Prins, et al.
Nature Communications|July 8, 2022
A third vaccination with a single T cell epitope confers protection in a murine model of SARS-CoV-2 infectionIris N Pardieck, Tetje C van der Sluis, Esmé T I van der Gracht, et al.
NPJ Vaccines|March 20, 2021
Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory diseaseJoan E M van der Lubbe, Sietske K Rosendahl Huber, Aneesh Vijayan, et al.
Nature Immunology|December 23, 2021
Prolonged activation of nasal immune cell populations and development of tissue-resident SARS-CoV-2-specific CD8+ T cell responses following COVID-19Anna H E Roukens, Cilia R Pothast, Marion König, et al.
Mbio|October 12, 2021
Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 VariantsLinda van Oosten, Jort J Altenburg, Cyrielle Fougeroux, et al.
Pageof 3